In the TCGA breast cancer dataset, CCT2 amplification and/or overexpression was associated with worse outcome [62], in agreement with studies in gall bladder carcinoma [63] and with our current findings in NSCLC. The gene discussed is CCT2; the disease is non-small cell lung carcinoma.